glp-1-directed nmda receptor antagonism for obesity treatment Schematic illustration of monoagonists, dual agonists and triple Frontiers | GLP-1 Receptor Agonists:
Description
Weeks 13 through 16 (maintenance evaluation): If the current dose is producing results, you stay here
The FDA has only approved Ozempic for those who have diabetes and kidney disease
Wegovy and Saxenda are effective alternatives, with different dosing and results
Nanoassembly-mediated Exendin-4 derivatives to decrease renal retention
PlexusDx eliminates this problem by compounding medications from licensed 503A pharmacies at a fraction of that price
Supporting one system invariably supports the other
